A Takeda Pharmaceutical (TYO: 4502)-partnered program has delivered strong mid-stage data, sending shares in Neurocrine Biosciences (Nasdaq: NBIX) up 5%.
Top-line results from the Phase II SAVITRI study of NBI-1065845 show the trial met its primary and key secondary endpoints.
The San Diegan company is studying the first-in-class AMPA potentiator, a small molecule, for the treatment of major depressive disorder (MDD) as a second-line option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze